Twenty-three pharmaceutical companies were named and praised by the Ministry of Industry and Information Technology, among them Koren, Amendment, Xinlitai...

Recently, the official website of the Ministry of Industry and Information Technology announced the results of the review and evaluation of the 2020 National Technology Innovation Demonstration Enterprise.
In accordance with the requirements of the Ministry of Industry and Information Technology, the Ministry of Finance, the Measures for the Identification and Management of Demonstration Enterprises for Technological Innovation (Trial) and the Notice of the General Office of the Ministry of Industry and Information Technology on the Review and Evaluation of National Technology Innovation Demonstration Enterprises in 2020, the official review and evaluation of 196 National Technology Innovation Demonstration Enterprise Organizations identified and approved for review in 2017.
, five enterprises failed to report materials to abandon the review as required, one company failed the review evaluation, and a total of six enterprises of the national technology innovation demonstration enterprises were withdrawn.
of the 196 companies that passed the review were 23 pharmaceutical companies, including Colum Pharmaceuticals, Lizhu Pharmaceuticals, North China Pharmaceuticals and Correctional Pharmaceuticals.
(photo source: Mi net) data show that the demonstration enterprise of technological innovation refers to the enterprise with strong technological innovation ability in the main production of industry, with significant innovation performance and important demonstration and guidance role.
the basic criteria mainly include the following points: (i) have the core competitiveness and leading position.
the core technology of enterprise development and has independent intellectual property rights, the overall level of technology in the same industry in a leading position.
actively lead or participate in the development of international, national or industry technical standards.
(ii) has continuous innovation ability and research and development investment.
research and development investment accounted for more than 3% of annual sales revenue, there are sound research and development institutions or with domestic and foreign universities, scientific research institutions to establish a long-term and stable cooperative relations.
has strong potential for development in leading technology areas.
importance to the training, introduction and use of scientific and technical personnel and highly skilled personnel.
(iii) has the role of industry-driven and independent brands.
has a strong driving force or driving potential in the development of the industry.
focus on the management and innovation of independent brands, through competitive development, the formation of a unique brand, and enjoy considerable visibility in the market.
(iv) has a strong profitability and a high level of management.
3 consecutive years of profit, the overall financial situation is good, sales revenue and total profits showed a steady upward momentum, cash flow is sufficient.
established a relatively complete intellectual property management system and quality assurance system.
(v) has a strong ability to apply new technologies.
actively implement technological transformation, with the transformation capacity of major scientific and technological achievements, energy conservation and emission reduction has a strong demonstration role.
(vi) has an innovative development strategy and a culture of innovation.
importance to the innovation of enterprise management development strategy, and strive to create and form the innovation culture of enterprise, taking technological innovation and independent brand innovation as the important content of business development strategy.
Innovating is the trend of today, the health insurance bureau collection and follow-up control fee is a big trend, the future drug price pressure has become inevitable, product strength is the core of enterprise competition; Policy advances will make room for innovative drugs and promote explosive growth of innovative drugs.
this background, pharmaceutical companies more return to the nature of research and development, increase research and development investment, which can also be seen from the 23 pharmaceutical companies through the review of the data.
2020 results report shows that Lizhu Group's total research and development expenditure of 350 million yuan, an increase of 1.63 percent year-on-year, accounting for 6.87 percent of total revenue.
continues to focus on innovative pharmaceuticals and high-barrier complex preparations, focusing on cutting-edge technologies and clinically unseeded needs, and accelerating innovation and upgrading.
in biopharmacerie, Lizhu single resistance from the focus of the project, improve the team and optimize the platform three aspects to focus on the promotion.
and Colum Pharmaceuticals invested more in research and development, with more than 1.3 billion yuan invested in research and development in 2019, up 21.24 percent year-on-year and accounting for 7.66 percent of revenue.
first half of this year, the company invested 769 million yuan in research and development, up 15.48 percent year-on-year, accounting for 10.37 percent of revenue.
12 products have been approved for sale and 11 have been declared for production since 2020.
It is understood that from 2017 to date, Colum Pharmaceuticals has made great achievements in innovation, was approved for listing 49 items (first imitation / first 20 items), of which a total of 24 (34 specifications) varieties over-evaluation (11 for the first), including 10 varieties according to the new registration classification was approved;
2020 semi-annual report data show that during the reporting period, the company's research and development investment of 49.95 million yuan, up 26.48 percent year-on-year.
Although the investment in research and development is not high, but North China Pharmaceuticals has its unique research and development advantages, the report shows that the company has the domestic pharmaceutical industry's largest resources of medicinal microbial strains, the largest microbial new drug screening species and metabolites library, in the field of microbial sources of new drugs screening to reach the leading domestic level.
National Engineering Center for Pharmaceutical Microbial Drugs is the only national engineering research center in the field of microbiology in China.
Overall, the 23 pharmaceutical companies announced have their own special features in research and development, especially in the pharmaceutical industry, innovative drug research and development heat is increasing, the number of new drugs approved continues to be high, but in 2017 innovative drugs accounted for China's drugs The proportion of sales is 5 per cent - there is plenty of room for improvement in the proportion of sales of innovative drugs in China, which is expected to reach 30 per cent by 2023 and 50 per cent by 2028, caused by a number of benefits.
recently, in the CPhI and P-MEC China 2020 overseas promotion through train and pharmaceutical foreign trade situation online broadcast, Seberan learned that in the first half of the year, western medicine imports and exports reached 45.693 billion U.S. dollars, an increase of 9.4% over the same period last year, of which exports of 23.640 billion U.S. dollars increased by 13.13 percent, imports of 22.053 billion U.S. dollars increased by 5.65 percent.
and the outbreak will bring about a reshaping of the global pharmaceutical industry, Seber blue at the meeting was informed that the outbreak prompted countries to pay more attention to public health security, but also accelerated the global pharmaceutical industry chain supply chain restructuring.
long term, with the introduction of incentive policies, international competition will intensify, China's products in the global market competition is facing challenges.
And innovation ability, coupled with the accumulation of pipelines in the past, has largely decided the future competitive landscape, especially the first innovative drugs continue to receive attention from the capital market, can effectively reduce research and development risks and maintain market exclusiveness, will directly enhance the competitiveness of domestic pharmaceutical companies in the global market.
the strength of research and development, by January 2018, there were 4,134 pharmaceutical companies in new drug research and development worldwide, with China having the third largest number of new drug research and development companies in Canada, accounting for 5%.
china has the fourth largest number of clinical studies in the world, and China has the world's largest number of biopharmaceity research and development.
, especially after 2000, China's research and development has been rapidly improved.
, it is worth noting that China's innovative drug research and development mainly focus on follow-up innovation, investment scale and risk are much lower than the global innovation drug.
background, how pharmaceutical companies can reduce costs, improve efficiency and improve innovation ability is an issue that the whole industry needs to consider.
.